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Abstract
Background:  An assessment of the correlation between anti-malarial treatment outcome and molecular
markers would improve the early detection and monitoring of drug resistance by Plasmodium falciparum. The
purpose of this systematic review was to determine the risk of treatment failure associated with specific
polymorphisms in the parasite genome or gene copy number.
Methods: Clinical studies of non-severe malaria reporting on target genetic markers (SNPs for pfmdr1, pfcrt, dhfr,
dhps, gene copy number for pfmdr1) providing complete information on inclusion criteria, outcome, follow up and
genotyping, were included. Three investigators independently extracted data from articles. Results were stratified
by gene, codon, drug and duration of follow-up. For each study and aggregate data the random effect odds ratio
(OR) with 95%CIs was estimated and presented as Forest plots. An OR with a lower 95th confidence interval >
1 was considered consistent with a failure being associated to a given gene mutation.
Results: 92 studies were eligible among the selection from computerized search, with information on pfcrt (25/
159 studies), pfmdr1 (29/236 studies), dhfr (18/373 studies), dhps (20/195 studies). The risk of therapeutic failure
after chloroquine was increased by the presence of pfcrt K76T (Day 28, OR = 7.2 [95%CI: 4.5–11.5]), pfmdr1
N86Y was associated with both chloroquine (Day 28, OR = 1.8 [95%CI: 1.3–2.4]) and amodiaquine failures (OR
= 5.4 [95%CI: 2.6–11.3, p < 0.001]). For sulphadoxine-pyrimethamine the dhfr single (S108N) (Day 28, OR = 3.5
[95%CI: 1.9–6.3]) and triple mutants (S108N, N51I, C59R) (Day 28, OR = 3.1 [95%CI: 2.0–4.9]) and dhfr-dhps
quintuple mutants (Day 28, OR = 5.2 [95%CI: 3.2–8.8]) also increased the risk of treatment failure. Increased
pfmdr1 copy number was correlated with treatment failure following mefloquine (OR = 8.6 [95%CI: 3.3–22.9]).
Conclusion: When applying the selection procedure for comparative analysis, few studies fulfilled all inclusion
criteria compared to the large number of papers identified, but heterogeneity was limited. Genetic molecular
markers were related to an increased risk of therapeutic failure. Guidelines are discussed and a checklist for
further studies is proposed.
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Background
Early diagnosis and treatment of uncomplicated malaria
with anti-malarial drugs remains the mainstay of disease
control in endemic areas. The emergence and spread of
Plasmodium falciparum resistance to chloroquine (CQ) and
sulphadoxine/pyrimethamine (SP) has rendered these
two inexpensive, first-line anti-malarials ineffective in
most malarious areas of the world, and compromised
malaria control programmes [1,2]. To rationalize alterna-
tive anti-malarial drug policy, it is crucial to be able to pre-
dict and monitor parasite resistance and yet the challenges
are immense [3]. The in vivo test is widely used, but
requires substantial logistical and financial support and
its interpretation is confounded by factors such as reinfec-
tion, immunity, and pharmacokinetics [4]. In vitro tests
quantify the anti-malarial activity against parasites iso-
lated from infected individuals, but the correlation
between such assays and clinical outcome is mostly
unsubstantiated [5]. Identification of the molecular basis
of anti-malarial drug resistance and its relationship to
therapeutic failure represents a major advance in our abil-
ity to monitor anti-malarial drug resistance [6].
Linkage studies with parasite isolates from malaria
patients have demonstrated a close association between
the  pfcrt  K76T mutation and the in vitro chloroquine
resistant phenotype [7]. Sequence analyses of the multi-
drug resistance (Pfmdr) genes, initially thought to confer
resistance through gene and P-glycoprotein over-expres-
sion, have revealed a series of point mutations that were
associated with resistance [8]. More recently, gene copy
number has been associated with decreased susceptibility
to quinine, mefloquine, artemisinins, lumefantrine and
halofantrine [9]. Resistance to antifolates and sulphona-
mides is conferred by point mutations at specific codons
in the genes coding for the dihydrofolate reductase
(DHFR) and dihydropteroate synthase (DHPS) enzymes,
respectively, resulting in decreased affinity of the enzyme
for the drug [10]. The molecular basis of artemisinin sus-
ceptibility has not been established yet, although an asso-
ciation with SERCA/ATPase6 has been proposed [11].
Understanding the relationship between putative molecu-
lar markers, parasite resistance and treatment failure has
become a priority now that artemisin-based combination
therapy (ACT) has replaced monotherapies as the first-
line treatment of uncomplicated falciparum malaria [12].
In combination, the contribution of the individual com-
ponents of drug regimen cannot be disentangled from a
clinical study. Furthermore, recent studies have high-
lighted that withdrawal of chloroquine drug pressure may
lead to a reversion to chloroquine-susceptible phenotypes
[13], and these might have gone undetected if molecular
prevalence surveys had not been conducted [14]. Amodi-
aquine is one of the most widely used artemisinin partner
drugs in ACT, but the underlying mechanism of parasite
resistance is poorly characterized [15]. Sulphadoxine/
pyrimethamine (SP) is the only drug currently studied in
detail for intermittent preventive therapy (IPT) in preg-
nant women and infants, but neither the influence of anti-
folate resistance on IPT efficacy nor the impact of IPT on
the selection of drug resistant parasites has been compre-
hensively addressed.
Although it is not customary to change treatment policies
based on molecular studies alone, molecular studies from
Mali and Tanzania have demonstrated that a high preva-
lence of resistance makers can inform policy change
[16,17]. Hence, it is hoped that the identification of early
markers of resistance will facilitate more widespread
deployment of rational treatment policies that will retard
the emergence of antimalarial drug resistant [18].
A key step in the process of validating experimental find-
ings is to verify the correlation of parasite genetics with
clinical response of the host. Collating this information is
crucial to our ability to apply specific genetic markers to
predict treatment failure. The aim of the current study was
to conduct a systematic review and a meta-analysis of clin-
ical trials reporting on putative genetic markers of P. falci-
parum resistance.
Methods
Study identification
A computerized search was carried out to identify clinical
trials of treatments of non-severe malaria recording clini-
cal and parasitological outcomes as well as the presence or
absence of genetic polymorphisms or over-expression of
genes suspected to be involved in drug resistance. Refer-
ences were screened using a computerized literature
search of PubMed (last ten years, ending December 2008)
combining the terms [(malaria OR plasmodium)] with
different combination according to single nucleotide pol-
ymorphisms known to be associated with therapeutic fail-
ure: (pfmdr1 OR mdr1 OR mdr OR pfmdr); (pfcrt OR crt);
(pfdhfr OR dhfr OR dihydrofolate reductase); (pfdhps OR
dhps  OR dihydropteroate synthase). Abstracts, case
reports, editorials, basic sciences and nonhuman studies
were excluded.
Study selection
Three authors (SP, FdM & ALB) independently reviewed
abstracts and full text of the references identified to deter-
mine suitability for inclusion. Studies were included if
they met the criteria allowing a complete extraction of
data. Examiners were not blinded to authors, institutions
or journal names.Malaria Journal 2009, 8:89 http://www.malariajournal.com/content/8/1/89
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Inclusion criteria
Studies were included in the analysis if it was possible
from the publication to obtain all the distinguishing fea-
tures that follow:
1. Patients presenting non-severe falciparum malaria.
2. Rate of wild/mutated type for any codon position in
one or more of the P. falciparum genes known to be
involved in drug resistance.
3. Rate of treatment failure/success in the studied pop-
ulation
4. Clinical outcome assessment following WHO crite-
ria (1994 and subsequent versions)
5. Duration of the follow-up
6. Information on the area of the study
7. Drug used, schedule and total dose
Molecular genotyping for recrudescence/reinfection dis-
crimination (whatever the method used and the discrimi-
nate gene) was used to distinguish studies: studies using
genotyping were specified in the figures.
Data extraction
When possible, relevant information was extracted from
published tables or figures. If the data were not provided
in tabular form, they were extracted or estimated from the
body of the text, mostly by transformation of % to num-
bers of patients or number of mutations. The number of
outcome events (total number of therapeutic failures out
of included patients) and denominators (number of
mutant type and wild type) were extracted for each resist-
ance gene. Parasitological failures, irrespective of symp-
toms, were included as treatment failures and, when PCR
genotyping was used to distinguish between recrudes-
cence and reinfection, only the data from confirmed fail-
ure were used. Studies presenting only final odds ratios,
relative risk or genotype failure index, without showing
raw data from patients, were not included.
Studies were stratified according to gene; codon; drug;
length of the follow up or end-point. Secondary stratifica-
tion allowed selection of the most accurate study for each
gene, according to the drug used, the follow-up duration,
and reinfection/recrudescence genotyping.
Analytical strategy and statistical method
The Odds Ratio (OR) was used rather than the Relative
Risk (RR) since the OR compares the proportion of thera-
peutic failures among the mutated parasites to the propor-
tion of therapeutic failures among the wild-type parasites,
while the RR compares the incidence of failure between
the mutated and the wild-type parasites. Considering the
numerous co-factors that could be involved in therapeutic
failure, OR seemed more accurate. The same limitation
could apply to genotype-failure index (GFI) that was
reported by few studies and that failed to take into
account the prevalence of the event in general population
[12]. For impact assessment, an odds ratio OR > 1
(95%CI) was considered consistent with therapeutic fail-
ure attributable to the mutant type of the parasite. A data-
base with the extracted data was created in
Comprehensive meta-analysis version 2 (Biostat, Engle-
wood, NJ 07631, USA). For each study, the impact (OR
95%CI), random effects, summary estimates and hetero-
geneity was calculated according to standard methods
[19,20].
Results are presented as funnel plots where a positive asso-
ciation between a given mutation and failure is depicted
by an OR95%CI lying on the right side of the graph ('B
side').
Results
Studies selection
The computerized search identified 963 papers, of which
557 papers describing basic sciences or methodological
experiments, and a further 202 papers without clinical fol-
low-up were excluded (figure 1). Efficacy data could not
be correlated with parasite genotype in 80 studies. Data
were extracted from the remaining 124 studies, although
32 were subsequently excluded due to the lack of clinical
failure, the absence of mutation, or the fixation of muta-
tion in the whole parasite population. Hence complete
information could be extracted from a total of 92 eligible
studies.
Pfmdr1 gene polymorphism
Only the polymorphism at codon 86 (N86Y) was
assessed, since few studies addressed the other codons of
other known polymorphisms. Of the 38 analysed studies,
12 were excluded mostly because it was impossible to
extract data on the relationship between failures and gen-
otypes. 22 studies using chloroquine and six studies using
amodiaquine were included. Eleven of the chloroquine
studies had a 14-day follow-up [21-31], ten had 28-day
follow-up [32-41], and one had a 42-day follow-up [42].
Genotyping for reinfection/recrudescence was available
for 3/11, 8/10 and 1/1 of these studies, respectively (Fig-
ure 2).
The risk of therapeutic failure was greater for patients har-
bouring the N86Y pfmdr1 polymorphism with an Odds
Ratio (OR) of 2.2 (95%CI: 1.6 – 3.1, p < 0.001) for the
studies with 14-day follow-up and 1.8 (95%CI: 1.3–2.4, pMalaria Journal 2009, 8:89 http://www.malariajournal.com/content/8/1/89
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< 0.001) for those with 28-day follow-up. For the 7 studies
with 28-day follow-up in which recurrent infection were
genotyped, the OR was 1.9 (95%CI: 1.3–2.7, p < 0.001).
To avoid potential publication bias, the number of miss-
ing studies that would nullify the observed effect was
computed using Classic fail-safe N statistics [20]. The fail-
safe number was high (N = 60), indicating the value of
this marker will probably not be changed by future stud-
ies. All but five studies (two with 14 days follow-up and
three with 28 days follow-up) showed an OR > 1,
although only eight (36%) had a lower confidence limit >
1.
Six studies using amodiaquine monotherapy were
included in the analysis [31,32,36,39,43,44], with the
N86Y mutation associated with an OR of 5.4 (95%CI: 2.6
– 11.2, p < 0.001) (Figure 3). Genotyping for reinfection/
recrudescence was used in five of these studies.
Pfcrt gene polymorphism
Overall 42 studies were identified following chloroquine
treatment, of which 13 were excluded due to missing data.
Of the 25 studies included (13 with 14 days of follow-up
[21-23,25,26,28,29,31,45-49] and 12 with 28 days of fol-
low up [35-40,50-55]), genotyping was available for 13
(52%), eight of which had a 28-day follow up. The OR for
failure associated with the K76T mutation was 2.1
(95%CI: 1.5–3.0, p < 0.001) and 7.2 (95%CI: 4.5 – 11.5,
p < 0.001) for the 14-day and the 28-day studies, respec-
tively (Figure 4). All but one study (14-day follow-up)
showed an OR > 1 and 11 (44%) had a lower confidence
limit > 1. Of the twelve 28-day studies, seven had a lower
confidence limit > 1. In the eight studies with genotyping
of the recurrent infection the OR for recrudescence by day
28 was 5.1 (95%CI: 3.1–8.45, p < 0.001). The number of
missing studies that would nullify the observed effect was
77, meaning that 77 'null' studies would be required in
order for the combined 2-tailed p-value to exceed 0.05.
Pfmdr1 N86Y and Pfcrt K76T associated polymorphisms
In five studies following chloroquine treatment [21-
23,34,35], data on polymorphisms at both the pfmdr1
N86Y codon and pfcrt K76T codon were available with
PCR genotyping, although only two studies had a 28-day
follow up [34,35]. The combined OR was 3.9 (95%CI: 2.6
– 5.8, p < 0.001) with a corresponding fail-safe number of
40 supporting a strong association between these markers
and therapeutic failures. All but one study had an OR > 1,
and two had a lower confidence limit > 1.
3 studies [31,43,44] including 172 patients assessed the
relationship of Pfmdr1  N86Y and Pfcrt  K76T polymor-
phisms and amodiaquine efficacy, one with a follow-up
of 21 days and the other with 28 days. Failures were dis-
tinguished by Msp2 genotyping. The OR was 4.0 (95%CI:
1.1 – 14.6, p < 0.001), although the fail-safe number
could not be calculated for two studies.
Flow chart for the selection of studies published during the last ten years Figure 1
Flow chart for the selection of studies published during the last ten years.
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Pfmdr N86Y predictive value of therapeutic failure with chloroquine treatment Figure 2
Pfmdr N86Y predictive value of therapeutic failure with chloroquine treatment. (A) Studies with 14 days follow-up 
(B) Studies with 28 days follow-up. Odds ratios (95% CI) are presented both numerically and graphically. The size of the forest 
plots is proportional to the relative weight of the study in the meta-analysis. The first row has the name of the first author and 
the year of publication of the study analysed. Target genes used for distinguishing reinfection to recrudescence are indicated 
when available. The red plot is the total OR for the listed studies.
Study name Statistics for each study Events / Total Subgroup within study
Odds Lower Upper 
ratio limit limit p-Value Group-A Group-B
Mockenhaupt 2005 2,470 1,434 4,257 0,001 86 / 127 45 / 98 14 Days Msp1 - Msp2
Huaman 2004 20,000 0,930 429,904 0,056 4 / 5 1 / 6 14 Days Glurp
Djimdé 2001 3,187 1,586 6,406 0,001 46 / 97 15 / 68 14 Days no
Basco 97 0,528 0,044 6,337 0,614 19 / 37 2 / 3 14 days no
Jelinek 2002 0,949 0,422 2,132 0,899 20 / 80 13 / 50 14 days no
Tinto 2003 2,009 0,760 5,312 0,160 12 / 25 17 / 54 14 days no
Tagelsir 2006 1,232 0,377 4,031 0,730 69 / 125 6 / 12 14 days no
Flueck 2000 1,347 0,397 4,570 0,633 12 / 26 7 / 18 14 days no
Khalil 2005 18,452 2,271 149,908 0,006 52 / 83 1 / 12 14 days no
Dorsey 2001 2,333 0,086 63,304 0,615 10 / 23 0 / 1 14 days no
Ochong 2003 19,200 3,097 119,049 0,002 24 / 26 5 / 13 14 days no
2,238 1,638 3,057 0,000
0,01 0,1 1 10 100
Favours A Favours B
Pfmdr N86Y - CQ - D14
Meta Analysis
Study name Statistics for each study Events / Total Subgroup within study
Odds Lower Upper 
ratio limit limit p-Value Group-A Group-B
Duraisingh 97 2,143 0,627 7,329 0,224 18 / 32 6 / 16 28 days Msp1-Msp2-Glurp
Nagesha 2001 2,591 1,140 5,890 0,023 38 / 78 11 / 41 28 days Msp1-Msp2
Pillai 2001 0,579 0,161 2,075 0,401 7 / 18 11 / 21 28 Days Msp1 - Msp2
Happi 2003 4,000 0,649 24,657 0,135 12 / 21 2 / 8 28 Days Msp1 - Msp2 - Glurp
Happi 2006 6,483 2,510 16,742 0,000 47 / 76 7 / 35 28 Days Msp2
Sarr 2005 0,246 0,012 4,966 0,361 0 / 11 4 / 29 28 days Msp1
Ojurongbe 2007 1,184 0,544 2,574 0,671 17 / 42 27 / 74 28 days Msp2
Ursing 2007 1,333 0,564 3,151 0,512 116 / 174 15 / 25 35 days Msp2
Sutherland 2002 45,259 5,811 352,489 0,000 26 / 53 1 / 48 28 days no
Mita 2003 38,250 3,913 373,865 0,002 3 / 5 2 / 53 28 days no
Bell 2008 0,850 0,447 1,616 0,620 134 / 353 18 / 43 42 days Msp2
1,772 1,294 2,426 0,000
0,01 0,1 1 10 100
Favours A Favours B
Pfmdr N86Y - CQ - D28
Meta Analysis
A 
B Malaria Journal 2009, 8:89 http://www.malariajournal.com/content/8/1/89
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Pfdhfr gene polymorphism
Polymorphisms at codons 51, 59 and 108 single mutants
and the triple mutant (51 + 59 +108) were studied when
SP was used to treat patients. Each single mutant was con-
sidered irrespective of the presence or absence of other
Pfdhfr mutations. It was not possible to derive from pub-
lished papers if Pfdhfr 108 single mutants were or not
linked with double or triple mutations. In total informa-
tion on Pfdhfr 108 single mutant was available in 18 stud-
ies with follow-up to 14 days and 21 days in six [47,56-
60] and two [61,62] of these studies respectively, leaving
ten studies with 28 days follow-up [55,63-71] (Figure 5).
The OR for the 18 studies was 2.1 (95%CI: 1.4–3, p <
0.001) and was 3.5 (95%CI: 1.9–6.3, p < 0.001) for the 10
studies with 28 days of follow-up, with a fail-safe number
of 13. Only three studies showed a lower confidence limit
> 1, including the study with the highest relative weight
and no genotyping. The OR for codon 51 and 59 single
mutants were 1.7 (95%CI: 1.0–3.0, p = O.038) and 1.9
(95%CI: 1.4–2.6, p < 0.001), respectively. The same limi-
tation regarding the possible association with other muta-
tions should be taken into account for the interpretation
of these results.
Sixteen studies concerning the triple Pfdhfr  mutant
(51+59+108) were included [55,56,61,63,65-67,72-80],
of which nine had 28 days of follow up with genotyping
available in eight of these. The overall OR was 4.3
(95%CI: 3.0–6.3, p < 0.001) with a fail-safe number of 22
(Figure 6). Four studies with a 28-day follow-up had a
lower confidence limit > 1 and a corresponding fail-safe
number of 88. In the eight studies with PCR adjusted out-
come at day 28 the OR was 3.1 (95%CI: 2.0 – 4.9; p <
0.001).
For three studies testing one, two and three of the Pfdhfr
SNPs, the overall ORs for the triple mutant was 3.9
(95%CI: 2.5 – 6.2, p < 0.001) compared to 2.1 (95%CI:
1.4 – 3.3, p < 0.001) for the single mutant. Only two stud-
ies testing on the same patients single (108) and triple
(51–59–108) mutants, allowed the comparison of the
respective OR: 1.9 (95%CI: 0.4 – 8.9) and 11.1 (95%CI:
2.4 – 51.9). Thus the risk of therapeutic failure increases
with the number of mutations in Pfdhfr.
Pfdhps gene polymorphism
Fewer studies addressed the relationship between dihy-
dropteroate synthase (dhps) polymorphisms and thera-
peutic failures. In 20 studies the A437G or K540E
[33,47,55-57,59-61,63,64,67,69-71,76,78-82] single
mutations could be correlated with therapeutic failure,
with follow up ranging from seven to 28 days and geno-
typing confirmation available in 50%. The combined OR
for A437G was 1.5 (95%CI: 1.0–2.4, p = 0.065) with two
of the studies having a lower 95%CI > 1. Pfdhps double
mutant (437 + 540) were analysed in a further ten studies
Pfmdr N86Y predictive value of therapeutic failure with amodiaquine treatment Figure 3
Pfmdr N86Y predictive value of therapeutic failure with amodiaquine treatment. Studies with different follow-up 
were included. Odds ratios (95% CI), forest plots and studies description are similar to figure 1.
Study name Statistics for each study Subgroup within study
Odds Lower Upper 
ratio limit limit p-Value
Ochong 2003 12,000 1,645 87,523 0,014 14 days no
Holmgreen 2006 10,182 1,273 81,437 0,029 21 days Msp2
Duraisingh 1997 19,000 2,119 170,383 0,009 28 days Msp1-Msp2-Glurp
Happi 2006 5,022 1,051 23,984 0,043 28 days Msp2
Tinto 2008 1,685 0,495 5,730 0,403 28 days Msp1-Msp2
Ursing 2007 31,015 1,762 545,945 0,019 35 days Msp2
5,445 2,631 11,269 0,000
0,01 0,1 1 10 100
Favours A Favours B
MDR N86Y - AQ
Meta AnalysisMalaria Journal 2009, 8:89 http://www.malariajournal.com/content/8/1/89
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Pfcrt K76T predictive value of therapeutic failure with chloroquine Figure 4
Pfcrt K76T predictive value of therapeutic failure with chloroquine. (A) Studies with 14 days follow-up (B) Studies 
with 28 days follow-up. Odds ratios (95% CI), forest plots and studies description are similar to previous figures. One study 
with day 35 end point was included in the day 28 list since the difference seems to be weak in terms of late failure rate.
Study name Statistics for each study Events / Total Subgroup within study
Odds Lower Upper 
ratio limit limit p-Value Group-A Group-B
Basco 2002 9,95 0,55 181,66 0,121 42 / 97 0 / 6 14 days Msa1- Msa2
Schneider 2002 0,90 0,04 19,87 0,946 12 / 81 0 / 2 14 days Msa2
Huamann 2004 3,00 0,10 90,96 0,528 5 / 5 5 / 6 14 days Glurp
Mockenhaupt 2005 2,47 1,43 4,26 0,001 86 / 127 45 / 98 14 days Msp1 - Msp2
Djimdé 2001 18,76 6,94 50,75 0,000 56 / 96 5 / 72 14 days no
Flueck 2000 1,35 0,40 4,57 0,633 11 / 25 7 / 19 14 days no
Jelinek 2002 34,98 2,07 591,42 0,014 33 / 89 0 / 29 14 days no
Ochong 2003 286,20 12,81 6393,12 0,000 13 / 15 0 / 26 14 days no
Berens 2003 2,75 0,13 60,13 0,521 19 / 54 0 / 2 14 days no
Tinto 2003 5,47 0,67 44,90 0,114 10 / 63 1 / 30 14 days no
Khalil 2005 18,45 2,27 149,91 0,006 52 / 83 1 / 12 14 days no
Pati 2007 3,27 0,91 11,69 0,068 33 / 107 3 / 25 14 days no
Meissner 2008 0,32 0,16 0,62 0,001 70 / 171 35 / 51 14 days no
2,14 1,54 2,99 0,000
0,01 0,1 1 10 100
Favours A Favours B
Pfcrt K76T - CQ - D14
Meta Analysis
Study name Statistics for each study Events / Total Subgroup within study
Odds Lower Upper 
ratio limit limit p-Value Group-A Group-B
Mayor 2001 6,65 0,35 124,95 0,206 27 / 72 0 / 5 28 days Msa2
Maguire 2001 2,24 0,88 5,69 0,092 89 / 180 7 / 23 28 days Msp2
Nguyen 2003 4,64 0,56 38,59 0,155 15 / 57 1 / 14 28 days Msp1 - Msp2 - Glurp
Happi 2003 4,33 0,71 26,53 0,113 13 / 22 2 / 8 28 days Msp1 - Msp2 - Glurp
Sarr 2005 5,17 0,26 103,58 0,283 4 / 27 0 / 13 28 days Msp1
Happi 2006 3,27 1,17 9,12 0,024 49 / 89 6 / 22 28 days Msp2
Ojurongbe 2007 5,63 1,57 20,19 0,008 41 / 92 3 / 24 28 days Msp2
Ursing 2007 104,57 23,28 469,61 0,000 26 / 49 2 / 187 35 days Msp2
Sutherland 2002 25,00 3,26 191,81 0,002 25 / 74 1 / 50 28 days no
Nagesha 2003 1380,33 53,98 35298,09 0,000 50 / 51 0 / 20 28 days no
Ranjit 2004 90,47 4,77 1715,85 0,003 29 / 36 0 / 11 28 days no
Mayxay 2007 48,43 2,92 804,45 0,007 45 / 130 0 / 45 Blank no
7,17 4,47 11,50 0,000
0,01 0,1 1 10 100
Favours A Favours B
Pfcrt K76T - CQ - D28
Meta Analysis
A 
B Malaria Journal 2009, 8:89 http://www.malariajournal.com/content/8/1/89
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with different day follow-up
[55,56,61,65,69,70,73,76,83,84]. The overall OR was 3.9
(95%CI: 2.6–5.8, p < 0.001), although recurrent parasites
were genotyped in only five of these studies (Figure 7).
Pfdhfr – Pfdhps genes combined polymorphism
Since several treatment regimens were used, the analysis
of the combined Pfdhfr and Pfdhps mutants was restricted
to SP and the quintuple mutants of Pfdhfr (codons 51–
59–108) plus Pfdhps (codons 437 and 540). Three studies
with 28-day follow up were included [63,70,75] with gen-
otyping of recurrent infections available for two. The OR
for these studies was 5.2 (95%CI: 3.2 – 8.8, p < 0.001)
with a fail-safe number of 38. All the studies had an OR
and a lower confidence limit > 1.
In three studies, the predictive value of the Pfdhfr/Pfdhps
quintuple mutants could be compared with that of the
Pfdhfr triple mutants. In [63], the OR was 91.6 (95%CI:
11–717, p < 0.001) for triple Pfdhfr mutants and 24.7
(95%CI: 8.3–74.1, p < 0.001) for Pfdhfr/Pfdhps quintuple
mutant. In [75], the ORs were 2.2 (95%CI: 1.1–4.7, p <
0.001) and 2.0 (95%CI: 1.0–3.9, p < 0.001), respectively.
In [70], the ORs went from 10.3 to 13.4.
Pfmdr1 copy number
Only one study assessing pfmdr1 copy number and the
response to the treatment of mefloquine for P. falciparum
met the criteria for inclusion [85]. The OR for treatment
failure associated with pfmdr1  amplification was 8.6
(95%CI: 3.3–22.9, p < 0.001) for mefloquine mono-
therapy at 28 days and 2.6 (95%CI: 1.2–5.6) p = 0.01) at
42 days following mefloquine + three days artesunate. In
a study from the same site, treatment failure at day 42 fol-
lowing a four day regimen of artemether-lumefantrine
was higher in infections with pfmdr1 amplification: OR =
5.1 (95%CI: 1.4–20, p = 0.012).
Pfdhfr S108N predictive value of therapeutic failure with Sulfadoxine-pyrimethamine Figure 5
Pfdhfr S108N predictive value of therapeutic failure with Sulfadoxine-pyrimethamine. Studies with different fol-
low-up were included. S108N point mutation was considered irrespective of the presence of other mutations at different Pfdhfr 
codons. Studies were stratified according first to the duration of the follow-up, second to the use of genotyping for recrudes-
cence, third to the date of publication.
Study name Statistics for each study Events / Total Subgroup within study
Odds Lower Upper 
ratio limit limit p-Value Group-A Group-B
Basco 2000 6,687 0,363 123,322 0,201 7 / 48 0 / 18 14 Days Msp1-Msp2-CSP
Khalil 2005 2,463 0,122 49,532 0,556 5 / 38 0 / 7 14 Days Msp1-Msp2-Glurp
Ibon Rallon 1999 2,147 0,103 44,695 0,622 3 / 40 0 / 11 14 Days no
Jelinek 1999 0,950 0,184 4,912 0,951 19 / 34 4 / 7 14 Days no
Fryauff 2002 0,407 0,018 8,981 0,569 18 / 21 6 / 6 14 Days no
Berens 2003 0,647 0,023 18,089 0,798 5 / 30 0 / 1 14 Days no
Omar 2001 19,500 3,792 100,289 0,000 33 / 44 2 / 15 21 Days Msp2
Curtis 1998 2,508 0,098 64,270 0,578 25 / 55 0 / 1 21 Days no
Aubouy 2003 1,395 0,151 12,925 0,769 10 / 53 1 / 7 28 Days Msp1 - Msp2
Hamour 2005 5,453 0,277 107,305 0,265 3 / 93 0 / 70 28 Days Msp1-Msp2
Happi 2005 12,014 1,562 92,390 0,017 29 / 99 1 / 30 28 Days Msp2
Ndounga 2007 1,207 0,047 31,075 0,910 17 / 60 0 / 1 28 Days Msp1-Msp2
Tinto 2007 0,259 0,045 1,486 0,130 2 / 20 6 / 20 28 Days yes
Khalil 2002 1,596 0,073 34,849 0,766 3 / 31 0 / 6 28 Days no
Kun 1999 5,262 2,322 11,927 0,000 33 / 70 10 / 69 28 Days no
ALifrangis 200310,308 1,384 76,799 0,023 37 / 238 1 / 57 28 Days no
Mayxay 2007 14,442 0,785 265,657 0,072 11 / 32 0 / 13 Blank no
A-Elbasit 2008 0,548 0,238 1,265 0,159 75 / 151 18 / 28 Blank no
2,168 1,428 3,291 0,000
0,01 0,1 1 10 100
Favours A Favours B
Pfdhfr S108N - SP
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Publication bias
There was no evidence of major publication bias in any of
the analyses from funnel-plot asymmetry. Exclusion of
any study did not substantially alter the summary esti-
mates.
Discussion
Despite the large number of studies published on anti-
malarial drug efficacy, as reviewed by Myint et al [86],
approximately 10% have specifically addressed the in vivo-
molecular correlates of resistance with criteria proposed
here. In total, 92 met the inclusion criteria, enrolling more
than 1,000 patients for each of the major molecular mark-
ers of drug resistance. For the drugs presented in this anal-
ysis, resistance occurs via two fundamentally different
mechanisms. Quinoline resistance is multigenic and epi-
static and, at least for chloroquine, affects drug accumula-
tion in the parasite food vacuole [87,88]. In contrast the
underlying molecular mechanism of antifolate resistance
involves accumulation of single mutations of the gene
encoding for the respective target enzymes [89].
Both pfcrt and pfmdr1 polymorphisms have been associ-
ated with chloroquine resistance. The Odds Ratio (OR) of
the pfcrt K76T mutation for therapeutic failure after chlo-
roquine exceeded 7.0 at 28 days and 2.0 at day 14. The
robustness of this association is confirmed by the high
number of null studies (77) required to negate it.
The association between CRT polymorphism and amodi-
aquine failure has not been adequately addressed. In the
analysis presented the pfmdr1 N86Y polymorphism was
the most frequently studied mutation and predicted fail-
ure to both chloroquine (1.9 (95%CI: 1.3–2.7, p <
0.001)) and amodiaquine (5.4 (95%CI: 2.6 – 11.2, p <
0.001)). However the association of this mutation and
clinical response to chloroquine was weak since few null
studies would challenge this observation. The predictivity
of the combined pfmdr1 + pfcrt was comparable (OR = 3.9
(95%CI: 2.6–5.8)) compared to pfcrt  alone and the
number needed to nullify this association decreased to 40.
However few studies combined both markers.
While the relationship between mutations in the Pfdhfr
and Pfdhps genes and parasite resistance to antifolates is
well described [90], the relative role of different mutations
in either gene in determining treatment outcome is less
clear. Although the degree of in vitro resistance and treat-
Pfdhfr N51I+C59R+S108N predictive value of therapeutic failure with Sulfadoxine-pyrimethamine Figure 6
Pfdhfr N51I+C59R+S108N predictive value of therapeutic failure with Sulfadoxine-pyrimethamine. Studies with 
different follow-up were included. The duration of the follow-up of the last study was supposed to be 28 days while not clearly 
indicated in the method by authors.
Study name Statistics for each study Events / Total Subgroup within study
Odds Lower  Upper 
ratio limit limit p-Value Group-A Group-B
Kublin 2002 10,311 3,395 31,317 0,000 32 / 50 5 / 34 7 Days no
Basco 2000 18,962 1,035 347,288 0,047 7 / 33 0 / 33 14 Days Msp1-Msp2-CSP
Sendagire 2005 1,975 0,644 6,062 0,234 6 / 33 9 / 89 14 Days Msp2
Djaman 2007 185,000 8,169 4189,623 0,001 12 / 14 0 / 18 14 Days no
Eriksen 2004 37,500 2,771 507,475 0,006 5 / 7 1 / 16 14 Days no
Omar 2001 637,000 11,503 35275,623 0,002 6 / 6 0 / 24 21 Days Msp2
Checchi 2002 7,326 0,369 145,544 0,192 17 / 38 0 / 4 28 Days Msp2
Kyabayinze 2003 2,244 1,063 4,737 0,034 41 / 108 12 / 56 28 Days Msp2
Aubouy 2003 0,800 0,080 8,021 0,850 9 / 54 1 / 5 28 Days Msp1 - Msp2
Van Den Broek 2004 1,265 0,336 4,761 0,729 3 / 28 13 / 150 28 Days Msp1-Msp2-Glurp
Mockenhaupt 2005 2,928 1,297 6,613 0,010 23 / 59 12 / 67 28 Days Msp1-Msp2
Happi 2005 94,632 12,077 741,479 0,000 29 / 48 1 / 63 28 Days Msp2
Ndounga 2007 9,000 1,835 44,146 0,007 15 / 35 2 / 26 28 Days Msp1-Msp2
Tinto 2007 5,800 0,902 37,279 0,064 3 / 6 5 / 34 28 Days yes
Basco 1998 91,000 1,464 5656,471 0,032 3 / 3 0 / 6 28 Days no
Mayxay 2007 9,143 1,389 60,165 0,021 4 / 6 7 / 39 Blank no
4,349 3,016 6,271 0,000
0,01 0,1 1 10 100
Favours A Favours B
Pfdhfr - N51I C59R S108N - SP
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ment failures to antifolates in this meta-analysis was
expected to be proportional to accumulating mutations of
Pfdhfr, there was no clear difference in the predictive val-
ues of single and triple mutants: OR = 3.5 (95%CI: 1.9–
6.3, p < 0.001) and OR = 4.3 (95%CI: 3.0–6.3, p < 0.001)
respectively. Most studies failed to analyse the link
between mutations at codons 51, 59 and 108. When data
were provided on the therapeutic failure rates associated
with each of these codons, it was not always possible to
carry out a cumulative analysis. The low difference for OR
between single and triple mutants suggest that single
mutants maybe markers for presence of other point muta-
tions. Due to these limitations, the only predictive value
that should be taken into account was the OR for triple
mutants. Several other mutant patterns or drug combina-
tions have been studied, but none provided sufficient data
to be included in the meta-analysis.
Overall polymorphisms in Pfdhps at positions 437 and
540 were predictive of therapeutic failure (OR = 3.9
(95%CI: 2.6–5.8, p < 0.001), but these data should be
considered with caution because of methodological issues
with the studies included (different duration of follow-up
and different use of genotyping). Pfdhfr + Pfdhps quintuple
mutants were analysed from three different studies, pro-
viding an OR = 5.2 (95%CI: 3.2–8.8, p < 0.001), with 38
null studies required -suggesting the high predictive value
of this composite genotype. It was impossible however to
clearly address the question of the predictive role of the
increase number of Pfdhfr + Pfdhps mutations since cumu-
lative data from the same patient were rare.
The meta-analysis confirmed and quantified the associa-
tion of the four genes studied and their underlying associ-
ated with the risk of therapeutic failure (Table 1).
However there are several caveats. Firstly the resistance of
the infecting parasite is only one determinant of treatment
outcome. Multiple studies have highlighted the impor-
tance of host immunity to the underlying therapeutic effi-
cacy in clinical studies. Such immunity is acquired over
time with multiple exposures and thus related to the age
of the patient and the transmission intensity [91]. Other
contributing factors include the biomass of parasites at
the start of treatment, the patient's adherence to treat-
ment, the dose of drug used and its adequate absorption
[92]. There were no enough studies in the present analysis
for a subgroup or multivariate analysis incorporating age
and other confounding factors, which reduces the power
of the analysis to detect independent parasite factors asso-
ciated with treatment failure.
Pfdhps 437 – 540 predictive value of therapeutic failure with Sulfadoxine-pyrimethamine Figure 7
Pfdhps 437 – 540 predictive value of therapeutic failure with Sulfadoxine-pyrimethamine. Odds ratios (95% CI), 
forest plots and studies description are similar to previous figures. Studies were stratified according first to the duration of the 
follow-up, second to the use of genotyping for recrudescence, third to the date of publication.
Study name Statistics for each study Events / Total Subgroup within study
Odds Lower Upper 
ratio limit limit p-Value Group-A Group-B
Kublin 2002 5,306 1,945 14,478 0,001 30 / 51 7 / 33 7 Days no
Basco 2000 1,463 0,298 7,179 0,640 3 / 23 4 / 43 14 Days Msp1-Msp2-CSP
Sendagire 2005 7,124 0,408 124,542 0,179 15 / 95 0 / 18 14 Days Msp2
Alker 2008 5,364 2,239 12,851 0,000 59 / 125 7 / 49 14 Days no
Kublin 1998 36,630 1,991 673,800 0,015 21 / 21 13 / 24 14 Days no
Omar 2001 3,808 0,743 19,512 0,109 9 / 11 26 / 48 21 Days Msp2
Van Den Broek 2004 0,750 0,260 2,162 0,594 6 / 78 10 / 100 28 Days Msp1-Msp2-Glurp
Happi 2005 11,800 4,220 32,998 0,000 24 / 44 6 / 65 28 Days Msp2
Kun 1999 2,200 0,712 6,793 0,170 11 / 17 25 / 55 28 Days no
Mayxay 2007 18,231 0,668 497,447 0,085 1 / 1 6 / 45 Blank no
3,855 2,565 5,793 0,000
0,01 0,1 1 10 100
Favours A Favours B
DHPS 437-540
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Second, most of the studies included were conducted in
Africa over the past 10 years, limiting the relevance of the
conclusions in space and time [93]. For instance, during
the study period chloroquine resistance was well estab-
lished, and failure and prevalence of mutations rates were
often at saturation, decreasing the power to detect a signif-
icant association. In view of the low number of studies
meeting inclusion criteria, it was not possible to compare
the OR between areas or periods with low mutation rates
to areas or periods with mutations close to fixation.
Third, only published studies indexed in PubMed were
considered for this meta-analysis, and one cannot exclude
a publication bias towards positive studies. However, con-
sidering the number of null studies needed to change the
data obtained, the effect of unpublished studies is likely to
be limited.
Fourth, study methodology varied with respect to inclu-
sion criteria, age of subjects, treatment schedules, PCR
methods and reporting, level of transmission at trial site.
A frequent reason for excluding a study was insufficient
details in the paper to allow coherent data extraction.
Moreover, approximately half of the studies included fol-
lowed patients for only 14 days (Table 1), and as such will
not identify late treatment failures, often the earliest man-
ifestation of resistance [94]. Genotyping of recurrent
infections to distinguish between re-infection and recru-
descence was only available in 53% of studies assessed.
When the analyses were restricted to studies where true
failures could be determined, the ORs varied significantly
and power was lost.
Lastly, the proportion of patients studied for molecular
markers represents a fraction of those enrolled or analysed
at the end of follow-up. As no explanation is given for
patient attrition, a selection bias cannot be excluded.
Conclusion
Recent initiatives, such as the consensus meeting on use of
genotyping in clinical trials [95] and the World-Wide
Antimalarial Resistance Network [96], will hopefully pro-
vide guidelines on how to analyse and report field data on
clinical, in vitro, molecular and pharmacokinetic determi-
nants of resistance. As a result of these methodological
issues, when inclusion criteria were applied, very few stud-
ies were eligible for the meta-analysis compared to the
number of studies identified. Despite the limitations
listed above, the results of this meta-analysis were reassur-
ingly homogeneous (funnel plots were highly symmetri-
cal) for all markers except pfmdr1 + pfcrt for chloroquine.
While the trials considered studied mostly monotherapies
with variable degrees of parasite resistance, these results
are still relevant now that combinations have become
standard treatment of uncomplicated malaria. Amodi-
aquine and SP are used combined with artesunate and
with each other. SP is currently the drug of choice for
intermittent preventive treatment (IPT) in pregnancy and
infancy. However, data on amodiaquine are limited and
the relevance of the genetic mechanisms of resistance of
chloroquine to other quinolines (pyronaridine, piper-
aquine) used in these combinations remains to be estab-
lished.
Table 1: Odds ratios related to polymorphisms linked to resistance, according to the drug and the duration of the follow-up. 
Genotyping (gen.) means that analyse was limited to studies that discriminate between reinfection and recrudescence.
Gene Polymorphism Drug Follow-up (genotyping) Odds Ratio Confidence intervals 95% Nb of studies
Pfmdr N86Y Chloroquine 14 2.2 1.6 – 3.1 11
- - 28–42 1.8 1.3 – 2.4 11
- - 28 (gen.) 1.9 1.3 – 2.7 7
- Amodiaquine 14–21–28 5.4 2.6 – 11.2 6
Pfmdr Copy number Mefloquine 28 8.6 3.3 – 22.9 1
- Mefloquine + artesunate 42 2.6 1.2 – 5.6 1
Pfcrt K76T Chloroquine 14 2.1 1.5 – 3.0 13
- - 28 7.2 4.5 – 11.5 12
- - 28 (gen.) 5.1 3.1 – 8.45 8
Pfmdr + Pfcrt N86Y + K76T Chloroquine 14–28 3.9 2.6 – 5.8 5
Pfdhfr 108 Sulphadoxine-pyrimethamine 14–28 2.1 1.4 – 3.0 18
108 - 28 3.5 1.9 – 6.3 10
51 - 14–28 1.7 1.0 – 3.0 6
59 - 14–28 1.9 1.4 – 2.6 13
51+59+108 - 14–28 4.3 3.0 – 6.3 16
51+59+108 - 28 (gen.) 3.1 2.0 – 4.9 8
Pfdhps 437 Sulphadoxine-pyrimethamine 14–28 1.5 1.0 – 2.4 12
437 + 540 - 14–28 3.9 2.6 – 5.8 10
Pfdhfr + Pfdhps Quintuple Sulphadoxine-pyrimethamine 14–28 5.2 3.2 – 8.8 3Malaria Journal 2009, 8:89 http://www.malariajournal.com/content/8/1/89
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With the extended use of combination therapies including
old and newer drugs, genetic markers can discriminate the
individual role of each component. Obviously more
research is needed into the molecular basis of resistance,
which are largely unknown especially for artemisin com-
pounds. Early mapping of known and new resistance
genes might be achieved by genome-wide scanning of pol-
ymorphisms [97].
Whatever the drug to be tested and the mutation to be sur-
veyed, it is of utmost importance to reach a consensus on
the methodology of futures studies, especially if compari-
son between areas and time is the objective of the network
of team involved in molecular surveillance of drug resist-
ance. A checklist is proposed here (Table 2), including a
series items which need to be fulfilled before designing a
study and before preparing data report. This template
could be used by colleagues to increase the portability of
molecular studies. It could be amended with the experi-
ence of experts in the field.
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